Search for a trial

Immunogenicity of HPV-vaccination in a reduced-dose schedule

To study the kinetics of the vaccine-induced antibody response against HPV16/18 after a two-dose schedule by measuring these antibody responses at approximately 7, 12, 24, 36, 48, 60, 72, 84, 96, 108 and 120 months following the first dose of HPV-…

The safety and cost-effectiveness of discontinuing disease-modifying therapies in stable relapsing-onset multiple sclerosis (DOT-MS): a randomized rater-blinded multicenter trial.

The aim of this study is to identify whether it is possible to safely discontinue treatment in stable RRMS patients who have shown no evidence of active inflammation in the years prior to inclusion in terms of the return of inflammatory disease…